HALAVEN Drug Patent Profile

When do Halaven patents expire, and what generic alternatives are available?

Halaven is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-eight patent family members in fourteen countries.

The generic ingredient in HALAVEN is eribulin mesylate. Fifteen suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Halaven

A generic version of HALAVEN was approved as eribulin mesylate by GLAND on April 5^th, 2024.

Summary for HALAVEN

International Patents:	38
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HALAVEN

Paragraph IV (Patent) Challenges for HALAVEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HALAVEN	Injection	eribulin mesylate	1 mg/2 mL	201532	1	2019-12-20

US Patents and Regulatory Information for HALAVEN

HALAVEN is protected by one US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	AP	RX	Yes	Yes	RE46965*PED				Y
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	AP	RX	Yes	Yes
Eisai Inc	HALAVEN	eribulin mesylate	SOLUTION;INTRAVENOUS	201532-001	Nov 15, 2010	AP	RX	Yes	Yes

International Patents for HALAVEN

See the table below for patents covering HALAVEN around the world.

Country	Patent Number	Title	Estimated Expiration
China	1312804	Macrocyclic analogs and methods of their use and preparation
Canada	3028453	INTERMEDIAIRES POUR LA PREPARATION D'ANALOGUES D'HALICHONDRINE B (INTERMEDIATES FOR THE PREPARATION OF ANALOGS OF HALICHONDRIN B)
Australia	2003284242
Norway	2022019

Supplementary Protection Certificates for HALAVEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1087960	1191021-3	Sweden		PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT EU/1/11/678/001-002, 2011-03-17 EG
1087960	132011901976051	Italy		PRODUCT NAME: ERIBULINA(HALAVEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/678/001-002, 20110317
1087960	C300493	Netherlands		PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
1087960	25/2011	Austria		PRODUCT NAME: ERIBULIN UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317

Investment Scenario, Market Dynamics, and Financial Trajectory for HALAVEN (Eribulin Mesylate)

Last updated: February 3, 2026

Summary

HALAVEN (eribulin mesylate) is an oncology drug developed by Eisai Inc., approved globally for metastatic breast cancer and liposarcoma. The product’s commercial success hinges on its clinical efficacy, regulatory landscape, competitive positioning, and market penetration strategies. This report analyzes HALAVEN’s current market environment, growth potential, competitive landscape, and financial prospects. Critical focus is placed on upcoming patent expirations, pipeline developments, regulatory approvals, and emerging market trends to inform strategic investment decisions.

---

1. Product Overview and Therapeutic Position

What is HALAVEN and how does it work?

• Active Ingredient: Eribulin mesylate
• Mechanism of Action: Microtubule dynamics inhibitor that disrupts mitosis, leading to apoptosis.
• FDA Approval: 2010 for metastatic breast cancer post-anthracycline and taxane therapy; 2016 for liposarcoma.
• Indications: Primarily used in late-line treatments for metastatic breast cancer and liposarcoma.
• Market Exclusivity: Patent expiration expected around 2025-2027, depending on jurisdiction.

---

2. Market Dynamics

Current Market Size and Growth Trajectory

Segment	Market Size (USD Billion, 2022)	CAGR (2022-2027)	Comments
Metastatic Breast Cancer (MBC)	7.9	7.5%	Driven by increasing prevalence and treatment advancements.
Liposarcoma (Soft Tissue Sarcomas)	2.1	8.2%	Rare cancer with rising recognition of eribulin’s efficacy.
Total Oncology Market (including eribulin segments)	320.0	6.8%	Reflects broader oncology sector growth.

Source: Global Oncology Market Report 2022 (Frost & Sullivan)

---

Competitive Landscape

Key Competitors	Mechanism	Market Share (2022)	Key Features	Patent Status
Halaven (Eisai)	Microtubule inhibitor	~20% (Breast & Sarcoma)	Proven efficacy, oral alternative under development	Patents expiring late 2020s
Ixempra (Ixabepilone)	Microtubule stabilizer	~15%	Approved in certain regions, similar niche	Expired or near expiration
Other agents	Various	Remaining share	e.g., taxanes, anthracyclines	Patent expirations vary

Note: Eribulin's unique mechanism and approvals sustain a competitive advantage in specific niches.

Regulatory Outlook

• Upcoming patent expiry: 2025–2027 in major markets (US, EU)
• Generic entry risks: High post-expiration, affecting pricing and margins.
• Pipeline developments: Limited proprietary competition; pipeline drugs are largely in early stages, reducing immediate competition risk.

---

3. Financial Trajectory

Revenue Performance

Year	Worldwide Sales (USD Million)	Growth Rate	Key Drivers
2019	425	-	Stabilized sales post-approval for liposarcoma
2020	418	-1.6%	COVID-19 impact, supply chain disruptions
2021	470	+12.4%	Recovery, expanded approvals, market penetration
2022	520	+10.6%	Increased adoption in key regions

Source: Eisai Annual Reports and Market Estimates

---

Profitability Metrics

Indicator	2022 Figures	Comments
Gross Margin	~60%	Reflects high-margin oncology portfolio
R&D Investment	USD 1.2 billion	Focused on pipeline and new formulations
EBITDA Margin	~25%	Indicates solid profitability, margins pressured near patent expiration

Forecasting Post-Patent Expiry

Scenario	Timing	Revenue Impact	Market Share Drop	Mitigation Strategies
Optimistic	2025	20-25% decline	Minimal due to strong brand and pipeline	Launch of biosimilars, new indications
Moderate	2026	30-35% decline	Significant generic competition	Cost reduction, geographic expansion
Pessimistic	2027	40%+ decline	Major erosion	Diversification, pipeline acceleration

Note: Sales erosion expected over 2-3 years post–patent expiry, consistent with industry trends.

---

4. Pipeline and R&D Focus

Near-term Pipeline Highlights

• Combination therapies: Trials for eribulin with immuno-oncology agents.
• Formulation innovations: Potential for oral eribulin.
• Indications expansion: Investigational use in non-small cell lung cancer and other solid tumors.

Development Stage	Product/Indication	Expected Approval	Strategic Value
Phase III	Eribulin + PD-1 inhibitor	2024-2025	Enhances efficacy profile
Phase II	Oral eribulin	2023-2024	Market convenience, patent extendability

Sources: ClinicalTrials.gov, Eisai R&D pipeline reports

---

5. Market Entry and Growth Strategies

Pricing and Reimbursement

• Premium positioning in niche indications.
• Reimbursement agreements in key markets (US, EU, Japan).
• Differentiation through combination therapies and exclusive indications.

Geographical Expansion

Region	Growth Opportunity	Barriers	Strategic Approaches
US	Mature, high reimbursement	Patent expiry looming	Innovate, value-based pricing
EU	Similar to US	Stringent approval process	Local partnerships
Asia-Pacific	High growth, increasing oncology burden	Regulatory variability	Local manufacturing, tailored marketing

Post-Patent Market Strategies

• Biosimilar development through licensing and acquisition.
• Pipeline acceleration to diversify revenue streams.
• Market penetration in less saturated regions.

---

6. Investment Outlook and Risks

Opportunity	Rationale	Risks	Mitigation
Market niche strength	Proven efficacy in hard-to-treat populations	Patent expiration	Pipeline development, new indications
Expansion in Asia	Rapidly growing oncology markets	Regulatory hurdles	Local partnerships, phased launches
Pipeline products	Potential to extend franchise lifespan	Clinical failure	Strategic R&D investment

Key Financial Metrics to Watch

Metric	Observation Point	Implication
Sales growth rate	Pre- and post-patent expiry	Revenue resilience
Gross margin	During patent cliff	Profitability sustainability
Pipeline progress	Phase III milestones	Future growth potential
Regulatory decisions	New indications	Market expansion opportunities

---

Conclusion

HALAVEN remains a strategic asset within Eisai’s oncology portfolio. It demonstrates solid sales, strong clinical efficacy, and measurable growth but faces imminent generic competition starting around 2025. Investment strategies should account for patent expiration timelines, ongoing pipeline development, and regional expansion efforts. Companies with proactive R&D efforts and diversified portfolios are positioned to mitigate risks and capitalize on emerging opportunities in the evolving oncology landscape.

---

Key Takeaways

• Market dominance in niche indications ensures continued revenue until patent expiry (~2025–2027).
• Patent expiry risk mandates investment in pipeline and biosimilar strategies for revenue sustainment.
• Pipeline innovation (combinations, oral formulations) offers opportunities to extend lifecycle.
• Geographic expansion in Asia and emerging markets remains critical for future growth.
• Cost management and strategic partnerships are essential in managing margins during patent cliff transitions.

---

FAQs

1. When is eribulin's patent expiration expected in major markets?

Patent protection for HALAVEN is projected to expire between 2025 and 2027, varying by region. This timing risks generic entry and price erosion.

2. What are the main competitors for HALAVEN in oncology?

Key competitors include ixabepilone (Ixempra), taxanes, and other microtubule-targeting agents. Clinical differentiation and indication-specific approvals sustain HALAVEN’s niche positioning.

3. What pipeline developments could impact HALAVEN’s future?

Upcoming trials for combination treatments with immunotherapies, the development of oral formulations, and expansion into additional solid tumors are central to future growth.

4. How do regional reimbursement policies affect HALAVEN’s market prospects?

Reimbursement levels significantly influence sales; strategic partnerships and value-based pricing are key to market access, especially in Europe and Asia.

5. What strategies should investors pursue considering HALAVEN’s patent landscape?

Investors should monitor pipeline milestones, biosimilar developments, and regional expansion plans. Diversification into new indications and formulations can mitigate revenue decline post-patent expiry.

---

References

[1] Frost & Sullivan. Global Oncology Market Report 2022.
[2] Eisai Inc. Annual Reports 2019–2022.
[3] ClinicalTrials.gov. Eribulin studies and pipeline updates.
[4] US Food and Drug Administration (FDA). Drug approvals and patent information.